Trial Profile
An Open Label Single Arm Extension Study to Further Evaluate the Safety, Tolerability and Treatment Response of GBT440 in Patients With Sickle Cell Disease Who Participated in the Phase 1 Study GBT440-001
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2019
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors Global Blood Therapeutics
- 29 Jan 2019 According to a Global Blood Therapeutics media release, data from the phase 1/2 study (NCT02285088) and the open-label extension (NCT03041909) were published in the online Journal Blood, a peer-reviewed publication of the American Society of Hematology.
- 17 Jan 2019 Results of multiple doses of voxelotor in patients published in the Blood.
- 13 Feb 2018 Status changed from active, no longer recruiting to completed.